$599

Insulet Appoints Chief R&D Officer; FDA to Review Sandoz Generic Tirzepatide; Kailera Appoints Chief Affairs Officer; Resalis Doses First Patient in Ph1b Obesity Study

A series of cardiometabolic-related news items have been observed from Insulet, FDA/Sandoz, Kailera Therapeutics, and Resalis Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here